This page is intended as reference information for the general public in Great Britain.
What is Fragmin and what is it used for?
Fragmin is a solution for injection and it belongs to a group of medicines called low molecular weight heparins (LMWH) or antithrombotics. These medicines help prevent the formation of blood clots by thinning the blood.
Venous thromboembolism (VTE) is a condition where blood clots develop in the legs (deep vein thrombosis, DVT) or the lungs (pulmonary embolism, PE), e.g. after surgery, prolonged bed rest or in patients with certain types of cancer.
Fragmin can be used in many different conditions:
In adults, to prevent blood clots (venous thromboembolism) forming before and after an operation
Prevention of deep vein thrombosis in adult patients bedridden due to a medical condition but not limited to, for example heart failure and respiratory failure
To treat blood clots in adults
To treat blood clots in certain types of cancer and prevent their recurrence in adults
Fragmin is a Prescription Only Medicine.
If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Fragmin these can be found at the electronic Medicines Compendium (eMC).
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.